Filing summary
Company mismatch: The supplied filing is Owens & Minor, Inc. (NYSE: OMI), not Accendra Health Inc. It is a Form 10-Q for the quarter ended March 31, 2023. The unaudited statements are in thousands of dollars, except per-share data.
Business context and reporting period
Owens & Minor operates Products & Healthcare Services, which includes medical distribution, outsourced logistics and medical products, and Patient Direct, which provides home healthcare products and services. Patient Direct includes Apria, acquired on March 29, 2022; consequently, the first-quarter 2022 comparison does not include Apria for the full quarter.
Key financial metrics
- Revenue: $2.523 billion, up 4.8% from $2.407 billion. Products & Healthcare Services revenue fell 10.2% to $1.915 billion; Patient Direct revenue rose 122.5% to $607.4 million.
- Profitability: Gross margin was $497.3 million, or 19.71% of revenue, versus $373.4 million, or 15.52%. Operating income fell to $9.8 million from $61.1 million. Net loss was $24.4 million, or $0.32 per diluted share, versus net income of $39.3 million, or $0.52 per diluted share.
- Cash flow: Operating activities provided $158.4 million, compared with $79.7 million. Investing activities used $34.2 million, including $51.5 million of capital expenditures, partly offset by asset-sale proceeds. Financing activities used $127.5 million. Cash, cash equivalents and restricted cash declined $3.0 million to $83.2 million; balance-sheet cash and cash equivalents were $66.8 million.
- Debt and liquidity: Total debt was $2.384 billion, including $2.362 billion of long-term debt excluding current maturities. The company had no borrowings under its $450 million revolving credit facility and reported $422 million available after letters of credit; its receivables financing agreement also had no borrowings and a $450 million maximum capacity. The company said it was in compliance with debt covenants.
- Balance sheet: Total assets were $5.310 billion and total liabilities were $4.386 billion at March 31, 2023. Current assets were $2.268 billion and current liabilities were $1.631 billion.
Material changes versus the prior-year quarter
- Revenue growth was driven by Apria’s inclusion and continued strength in Byram, while Products & Healthcare Services faced lower hospital demand, customer reliance on stockpiles, reduced COVID-19-related purchases and pricing pressure, particularly for gloves.
- Products & Healthcare Services segment operating income dropped to $1.8 million from $89.1 million. Patient Direct segment operating income increased to $45.8 million from $15.8 million, primarily reflecting Apria, Byram growth, fixed-cost leverage and efficiencies.
- Interest expense increased to $42.2 million from $12.0 million, principally because of acquisition-related debt and higher market rates. Exit and realignment charges increased to $15.7 million from $1.7 million; acquisition-related charges and intangible amortization totaled $22.2 million, down from $42.1 million.
Outlook, risks and unusual items
- The filing provides no specific earnings or revenue guidance. Management expected material additional 2023 costs for its operating-model realignment and information-technology initiatives, and said inflationary pressure and higher labor, occupancy and administrative costs continued; the ability to pass those costs to customers is limited.
- After quarter-end, NIOSH and FDA communications raised performance concerns about certain Halyard surgical N95 respirator lots and other masks. The company voluntarily stopped U.S. sales of referenced respirators and similar models while investigating and retesting. It could not estimate a possible loss; returns, recalls, remediation, regulatory action, litigation or supply disruption could materially affect results, financial condition or cash flows.
- The Philips Respironics recall affecting devices distributed by Apria may continue to create costs, supply constraints and revenue or operating impacts; recovery of costs from the manufacturer is uncertain.
- The IRS disputes the company’s transfer-pricing treatment for 2015–2018. Management said it had reserved adequately and did not expect a material impact, but noted that an adverse outcome could be material.
- Other sensitivities include interest rates, foreign currency, raw-material and freight costs, and substantial indebtedness. Management estimated that a 100-basis-point interest-rate increase could reduce annual future pretax earnings by approximately $7.2 million, after the interest-rate swap.
Important facts for investors to verify
- Confirm the intended issuer: this filing identifies Owens & Minor, not Accendra Health Inc.
- Assess whether the sharp decline in Products & Healthcare Services profitability persists and how much Patient Direct performance depends on Apria and Byram.
- Track debt, interest expense, refinancing needs—including approximately $254 million due in December 2024—and covenant compliance.
- Monitor the Halyard respirator and mask investigation for sales restrictions, recalls, customer claims, regulatory actions and any quantified financial exposure.
- Evaluate the Philips recall’s ongoing effects on patient care, product availability, costs and potential recoveries.
- Review actual spending and outcomes for the realignment and IT initiatives, and subsequent developments in the IRS dispute.